| Species |
Human |
| Protein Construction |
HGF (Gln32-Ser728)
Accession # P14210-1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human HGF R, His Tag at 1μg/ml (100 μl/Well) on the plate can bind HGF hFc Chimera, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
79.6 kDa (after cleavage of the signal peptide) |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 60-65 kDa corresponding to α chain and β chain based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS, 100 mM L-arginine (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Hepatocyte growth factor (HGF) is an important component of the pathophysiology of IR, with increased levels in most common IR conditions, including obesity. HGF has a role in the metabolic flux of glucose in different insulin sensitive cell types; plays a key role in β-cell homeostasis; and is capable of modulating the inflammatory response.HGF plays a central role in these metabolic disorders,HGF levels could be employed as a biomarker for disease status/progression, and HGF/c-Met signaling pathway modulators could effectively regulate IR and treat diabetes. |
| Synonyms |
Hepatopoietin-A; SF; HPTA; HGF; DFNB39; F-TCF; F-TCFB; HGFB |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
